Opsan Healthtech Private Limited

Vancomycin 1g Injection is a glycopeptide antibiotic used to treat severe bacterial infections, particularly those caused by Gram-positive organisms. It is often reserved for infections that are resistant to other antibiotics or when other treatments are not suitable.

-

💊 Medical Description

Active Ingredient:

Vancomycin hydrochloride

Formulation:

Injection (1g per vial)

-

Mechanism of Action:

Vancomycin works by inhibiting bacterial cell wall synthesis. It binds to the D-alanine-D-alanine portion of the bacterial cell wall precursor, preventing the formation of peptidoglycan cross-links and thus halting cell wall synthesis. This leads to bacterial cell lysis and death.

-

Indications:

Vancomycin is used to treat serious infections caused by Gram-positive bacteria, including:

Methicillin-resistant Staphylococcus aureus (MRSA) infections
Severe skin and soft tissue infections caused by Gram-positive organisms
Endocarditis, particularly in patients with allergies to beta-lactam antibiotics
Bone and joint infections (osteomyelitis)
Pneumonia, including hospital-acquired pneumonia (HAP)
Bacteremia caused by Gram-positive bacteria
Clostridium difficile-associated diarrhea (oral vancomycin)

-

Dosage and Administration:

For Adults:

The usual initial dose for serious infections is 1g to 1.5g every 12 hours (IV).
For severe infections, doses may be increased based on the infection severity and the patient’s weight.
IV infusion should be administered over a minimum of 60 minutes to prevent "Red Man Syndrome" (a histamine-related reaction).
Loading doses may be required for critically ill patients.

For Pediatric Patients:

Pediatric doses are based on the child’s weight, typically around 10-15 mg/kg every 6 to 8 hours.

Renal Adjustment:

Vancomycin is primarily eliminated through the kidneys. Patients with impaired renal function may require dosage adjustments to avoid toxicity.

-

Pharmacokinetics:

Absorption: Vancomycin is poorly absorbed from the gastrointestinal tract; therefore, it is administered intravenously or, in the case of C. difficile, orally.
Distribution: It distributes widely in body fluids, including pleural, pericardial, synovial, and ascitic fluids.
Half-life: Approximately 4 to 6 hours, but can be prolonged in patients with renal impairment.

-

Side Effects:

Common side effects may include:

Red Man Syndrome (flushing, rash, and hypotension, especially when infused too quickly)
Phlebitis (inflammation of the vein)
Nephrotoxicity (kidney damage), particularly with prolonged therapy or high doses
Ototoxicity (hearing loss), though rare

Serious adverse effects include:

Severe allergic reactions (anaphylaxis)
Clostridium difficile-associated diarrhea (from prolonged use)

-

Precautions:

Renal Impairment: Caution is required in patients with kidney problems, as vancomycin is primarily excreted through the kidneys.
Monitoring: Regular monitoring of serum vancomycin levels is recommended to avoid toxicity, particularly in patients with renal issues.
Infusion Rate: To minimize the risk of Red Man Syndrome, vancomycin should be infused over at least 60 minutes. Slower infusion rates may be necessary for patients at high risk of this reaction.

-

Compatibility:

Vancomycin can be administered intravenously with saline or dextrose solutions, but it should not be mixed with other medications in the same IV line unless compatibility is confirmed.

**Coplellor**(IXKIZUMAB) 80mg is not a recognized or approved medication name as of my latest update and may be a typographical error or a brand not widely recognized. However, **Ixekizumab**, which you mentioned alongside it, is a well-known biologic medication. Below is the accurate and detailed description for **Ixekizumab (80 mg)**:

---

### **Ixekizumab (Brand name: Taltz)**

**Dosage Form:**
Injection, 80 mg/mL in a single-dose prefilled syringe or autoinjector.

**Drug Class:**
Monoclonal antibody – **Interleukin-17A (IL-17A) inhibitor**

---

### **Indications:**

Ixekizumab is used to treat several autoimmune and inflammatory conditions, including:

* **Moderate-to-severe plaque psoriasis** in adults and children aged 6 years and older who are candidates for systemic therapy or phototherapy.
* **Psoriatic arthritis (PsA)** in adults (alone or in combination with conventional DMARDs like methotrexate).
* **Ankylosing spondylitis (AS)** / **Radiographic axial spondyloarthritis**.
* **Non-radiographic axial spondyloarthritis** with objective signs of inflammation.

---

### **Mechanism of Action:**

Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to **interleukin-17A (IL-17A)**, a pro-inflammatory cytokine involved in the pathogenesis of psoriasis and other inflammatory conditions. By inhibiting IL-17A, it reduces inflammation and the associated symptoms.

---

### **Dosage and Administration:**

* **Plaque Psoriasis (Adult):**
Initial dose: 160 mg (two 80 mg injections) subcutaneously at Week 0,
then 80 mg every 2 weeks through Week 12,
followed by 80 mg every 4 weeks.

* **Psoriatic Arthritis / Axial Spondyloarthritis:**
160 mg initial dose (two 80 mg injections), then 80 mg every 4 weeks.

Always follow specific dosing instructions provided by a healthcare provider.

---

### **Common Side Effects:**

* Injection site reactions (pain, redness)
* Upper respiratory infections
* Nausea
* Tinea infections (fungal)
* Headache

---

### **Warnings and Precautions:**

* **Infection risk:** Increases susceptibility to infections, especially fungal.
* **Hypersensitivity:** Reactions including angioedema and urticaria have been reported.
* **Inflammatory bowel disease:** May exacerbate or trigger new onset.

---

If you meant **“Coplellor”** as a specific brand or formulation of Ixekizumab, please double-check the spelling or provide additional context (such as country of origin), and I can help clarify further.